Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talineuren
- Development stage
- Phase 2
- Lead developer
- InnoMedica
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Talineuren (NI-101) is a recombinant human monoclonal antibody specifically designed to target and neutralize pathological forms of alpha-synuclein, including oligomers and fibrils. Developed by Neurimmune using its proprietary Reverse Translational Medicine (RTM) platform, the antibody was derived from B cells of healthy elderly individuals who showed no signs of cognitive or motor impairment, suggesting a protective immune response. Talineuren aims to slow or halt the progression of Parkinson's disease and other synucleinopathies by promoting the microglial clearance of toxic aggregates and blocking the cell-to-cell transmission of misfolded proteins. By targeting the extracellular alpha-synuclein species responsible for the spread of neurodegeneration, it seeks to preserve neuronal integrity and function.
- Other names
- NI101NI-101NI 101
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on talineuren.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talineuren.